Lyra Therapeutics (LYRA) News Today → The ONE AI Stock to own now. (It’s not Nvidia.) (From Weiss Ratings) (Ad) Free LYRA Stock Alerts $0.33 +0.01 (+3.09%) (As of 05/28/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 29 at 12:48 AM | markets.businessinsider.comMaintaining Hold on ProKidney: Balancing Market Potential Against Clinical UncertaintiesMay 21, 2024 | msn.comLyra to cut 75% of workforce in portfolio shakeupMay 21, 2024 | globenewswire.comLyra Therapeutics Announces Cost-Cutting Measures to Preserve CapitalMay 15, 2024 | finance.yahoo.comTarget upgraded, CVS downgraded: Wall Street's top analyst callsMay 7, 2024 | markets.businessinsider.comHold Rating on Lyra Therapeutics Amid Clinical Trial Setbacks and Financial UncertaintiesMay 7, 2024 | msn.comBTIG Downgrades Lyra Therapeutics (LYRA)May 7, 2024 | markets.businessinsider.comWhere Lyra Therapeutics Stands With AnalystsMay 7, 2024 | marketbeat.comLyra Therapeutics, Inc. (NASDAQ:LYRA) Receives Consensus Recommendation of "Hold" from AnalystsShares of Lyra Therapeutics, Inc. (NASDAQ:LYRA - Get Free Report) have received a consensus rating of "Hold" from the six analysts that are covering the stock, Marketbeat reports. One analyst has rated the stock with a sell recommendation, four have given a hold recommendation and one has given aMay 7, 2024 | marketbeat.comLyra Therapeutics (NASDAQ:LYRA) Cut to "Neutral" at HC WainwrightHC Wainwright downgraded shares of Lyra Therapeutics from a "buy" rating to a "neutral" rating and lowered their price objective for the company from $12.00 to $2.00 in a research report on Tuesday.May 6, 2024 | msn.comWhy Lyra Therapeutics Stock Is Down 93% TodayMay 6, 2024 | markets.businessinsider.comLyra Therapeutics's Phase 3 Enlighten Trial 1 Fails To Meet Primary Endpoint; Stock DownMay 6, 2024 | marketwatch.comLyra Therapeutics Shares Plummet 90% After Chronic Rhinosinusitis Drug Fails in StudyMay 6, 2024 | marketbeat.comTrading was temporarily halted for "LYRA" at 12:05 PM with a stated reason of "LULD pause." Trading set to resume at 12:05 PM. May 6, 2024 | investorplace.comWhy Is Lyra Therapeutics (LYRA) Stock Down 90% Today?May 6, 2024 | marketwatch.comLyra Therapeutics Lead Drug Candidate Fails in Phase 3 StudyMay 6, 2024 | globenewswire.comLyra Therapeutics Reports Topline Results from Phase 3 ENLIGHTEN 1 Trial for LYR-210 in Chronic RhinosinusitisMay 6, 2024 | marketbeat.comTrading was temporarily halted for "LYRA" at 07:05 AM with a stated reason of "News pending."May 3, 2024 | marketbeat.comQ2 2024 EPS Estimates for Lyra Therapeutics, Inc. (NASDAQ:LYRA) Decreased by AnalystLyra Therapeutics, Inc. (NASDAQ:LYRA - Free Report) - Analysts at HC Wainwright reduced their Q2 2024 EPS estimates for Lyra Therapeutics in a research report issued to clients and investors on Wednesday, May 1st. HC Wainwright analyst M. Caufield now anticipates that the company will post earninMay 2, 2024 | markets.businessinsider.comBuy Rating Affirmed for Lyra Therapeutics Amid Strong Phase 3 Prospects for LYR-210May 2, 2024 | finance.yahoo.comLyra Therapeutics First Quarter 2024 Earnings: Revenues Beat Expectations, EPS LagsMay 1, 2024 | markets.businessinsider.comBuy Rating Affirmed for Lyra Therapeutics Amid Favorable LYR-210 Trial Outcomes and Strategic CRS Market PositioningMay 1, 2024 | markets.businessinsider.comBuy Rating for Lyra Therapeutics Backed by Upcoming Catalysts and Market PotentialMay 1, 2024 | marketbeat.comLyra Therapeutics' (LYRA) "Buy" Rating Reiterated at HC WainwrightHC Wainwright reissued a "buy" rating and issued a $12.00 price objective on shares of Lyra Therapeutics in a research report on Wednesday.April 30, 2024 | globenewswire.comLyra Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate UpdateApril 26, 2024 | globenewswire.comLyra Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 26, 2024 | newsweek.comWorld's Best Digital Health Companies 2024 - TreatmentMarch 26, 2024 | finance.yahoo.comPrivate equity firms who hold 39% of Lyra Therapeutics, Inc. (NASDAQ:LYRA) gained 6.8%, institutions profited as wellMarch 25, 2024 | marketbeat.comLyra Therapeutics (NASDAQ:LYRA) Price Target Cut to $11.00Bank of America decreased their price target on shares of Lyra Therapeutics from $12.00 to $11.00 and set a "buy" rating on the stock in a research report on Monday.March 23, 2024 | finance.yahoo.comLyra Therapeutics Inc (LYRA) Posts Year-End Financial Results, Aligns with EPS ProjectionsMarch 22, 2024 | markets.businessinsider.comOptimistic Buy Rating for Lyra Therapeutics’ LYR-210 Amidst Phase 3 Trial and Market OpportunityMarch 22, 2024 | msn.comLyra Therapeutics files for $300M mixed shelfMarch 22, 2024 | marketbeat.comLyra Therapeutics (NASDAQ:LYRA) Receives "Buy" Rating from HC WainwrightHC Wainwright reissued a "buy" rating and set a $12.00 price objective on shares of Lyra Therapeutics in a research report on Friday.March 21, 2024 | globenewswire.comLyra Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateMarch 16, 2024 | marketbeat.comLyra Therapeutics, Inc. (NASDAQ:LYRA) Short Interest Down 13.6% in FebruaryLyra Therapeutics, Inc. (NASDAQ:LYRA - Get Free Report) was the target of a significant decline in short interest during the month of February. As of February 29th, there was short interest totalling 160,200 shares, a decline of 13.6% from the February 14th total of 185,400 shares. Based on an average daily trading volume, of 254,600 shares, the days-to-cover ratio is currently 0.6 days.March 15, 2024 | finance.yahoo.comLYRA Jul 2024 2.500 callMarch 15, 2024 | finance.yahoo.comLYRA Jul 2024 7.500 callMarch 15, 2024 | finance.yahoo.comLYRA Apr 2024 7.500 putMarch 15, 2024 | finance.yahoo.comLYRA May 2024 7.500 callMarch 3, 2024 | marketbeat.comArmistice Capital LLC Cuts Position in Lyra Therapeutics, Inc. (NASDAQ:LYRA)Armistice Capital LLC trimmed its position in Lyra Therapeutics, Inc. (NASDAQ:LYRA - Free Report) by 61.4% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,550,000 shares of the company's stock afterMarch 1, 2024 | globenewswire.comLyra Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)February 21, 2024 | finance.yahoo.comHere's What Could Help Lyra Therapeutics, Inc. (LYRA) Maintain Its Recent Price StrengthFebruary 14, 2024 | marketbeat.comLyra Therapeutics (NASDAQ:LYRA) Trading Down 1%Lyra Therapeutics (NASDAQ:LYRA) Shares Down 1%February 12, 2024 | bizjournals.comLyra Therapeutics invests in Mass. manufacturing with new HQJanuary 29, 2024 | businessinsider.comThese are the 7 healthcare startups primed to IPO when the market reopensJanuary 28, 2024 | msn.com15 Unhappiest States in the USJanuary 17, 2024 | finance.yahoo.comWhat Makes Lyra Therapeutics, Inc. (LYRA) a Good Fit for 'Trend Investing'December 30, 2023 | marketbeat.comLyra Therapeutics, Inc. (NASDAQ:LYRA) Sees Significant Decline in Short InterestLyra Therapeutics, Inc. (NASDAQ:LYRA - Get Free Report) was the target of a large decrease in short interest in December. As of December 15th, there was short interest totalling 172,600 shares, a decrease of 24.4% from the November 30th total of 228,300 shares. Based on an average trading volume of 237,900 shares, the days-to-cover ratio is currently 0.7 days.December 27, 2023 | benzinga.comLyra Therapeutics Stock (NASDAQ:LYRA) Dividends: History, Yield and DatesDecember 21, 2023 | marketbeat.comAnalysts Issue Forecasts for Lyra Therapeutics, Inc.'s FY2023 Earnings (NASDAQ:LYRA)Lyra Therapeutics, Inc. (NASDAQ:LYRA - Free Report) - Cantor Fitzgerald issued their FY2023 earnings per share estimates for shares of Lyra Therapeutics in a research report issued on Monday, December 18th. Cantor Fitzgerald analyst L. Chen forecasts that the company will post earnings per shareDecember 21, 2023 | marketbeat.comLyra Therapeutics' (LYRA) Overweight Rating Reiterated at Cantor FitzgeraldCantor Fitzgerald restated an "overweight" rating on shares of Lyra Therapeutics in a research report on Monday. Get Lyra Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for LYRA and its competitors with MarketBeat's FREE daily newsletter. Email Address Tech GIANT’s Plans to Revolutionize Crypto… (Ad)A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. Claim your free seat by clicking here now. LYRA Media Mentions By Week LYRA Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. LYRA News Sentiment▼0.150.82▲Average Medical News Sentiment LYRA News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. LYRA Articles This Week▼31▲LYRA Articles Average Week Get Lyra Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for LYRA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: PYPD News Today NEPH News Today MHUA News Today PAVM News Today RVP News Today IINN News Today FEMY News Today NMTC News Today MBOT News Today NXGL News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:LYRA) was last updated on 5/29/2024 by MarketBeat.com Staff From Our PartnersThe #1 Crypto That You Don’t Own… YetCrypto 101 MediaYou won't believe what Citigroup just did to it's depositorsAmerican Alternative4 Cryptos BETTER than BitcoinTrue Market InsidersHe Is Giving Away BitcoinCrypto Swap ProfitsA once-in-a-century investment opportunityStansberry ResearchWrite this ticker symbol down…StocksToTradeBill Clinton Backing Biden Replacement???The Freeport SocietyMust-See: Elon’s New Invention is Absolutely InsaneInvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lyra Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
